Document is current
Any future updates will be listed below
-
Authors
Wendler, Alexandra
Wehling, Martin
-
Funding
Funding for this research was provided by:
Ruprecht-Karls-Universität Heidelberg
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 24 May 2023
First Online: 6 June 2023
Declarations
:
: Not applicable.
: Not applicable.
: M. W. was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (= translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, LEO, Mundipharma, Novartis, Pfizer, Heel, IGAV, Polyphor, Helsinn, Allergan, Novo-Nordisk, Lilly, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie, und Daichii-Sankyo. A. W. declares no conflicts of interest.
